Illumina, Inc. $ILMN Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 15.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 523,448 shares of the life sciences company’s stock after selling 96,910 shares during the period. Teacher Retirement System of Texas’ holdings in Illumina were worth $49,712,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Parkside Financial Bank & Trust grew its position in shares of Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares in the last quarter. Quent Capital LLC purchased a new stake in Illumina in the 3rd quarter valued at $29,000. Cullen Frost Bankers Inc. acquired a new stake in shares of Illumina in the 2nd quarter worth $41,000. NewSquare Capital LLC raised its holdings in shares of Illumina by 604.9% during the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after acquiring an additional 369 shares during the period. Finally, Mather Group LLC. acquired a new position in shares of Illumina during the 3rd quarter valued at about $46,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Performance

NASDAQ ILMN opened at $153.95 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The company has a market cap of $23.52 billion, a P/E ratio of 34.52, a P/E/G ratio of 2.54 and a beta of 1.41. The stock has a 50-day moving average of $134.61 and a two-hundred day moving average of $112.77. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The business’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Insider Buying and Selling at Illumina

In related news, Director Scott Gottlieb bought 500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was purchased at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the acquisition, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. This trade represents a 4.16% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of analyst reports. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research note on Wednesday, January 7th. Robert W. Baird set a $109.00 price target on shares of Illumina in a report on Friday, October 31st. JPMorgan Chase & Co. upped their price objective on Illumina from $105.00 to $130.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Canaccord Genuity Group increased their price objective on Illumina from $112.00 to $130.00 and gave the stock a “hold” rating in a research report on Monday, December 22nd. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $124.47.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.